Imagine a future in which you age, but without the diseases your parents got. A future in which it doesn’t hurt to grow old.
At UNITY, we design therapeutics that prevent, halt, or reverse diseases of aging. Our medicines are designed to lengthen healthspan, the amount of time you live in good health.
When the world’s over-60 population doubles to two billion in 2050, one in four humans will be old.1 Historically, old age has meant arthritis, heart disease, kidney failure, loss of eyesight, and loss of hearing. We’re targeting fundamental mechanisms at the root of age-related diseases. Our medicines could make many debilitating consequences of aging as uncommon as polio.
1Ageing and health. World Health Organization. 2015 September:
http://www.who.int/mediacentre/factsheets/fs404/en/
Our initial focus at UNITY is on selectively eliminating senescent cells.
Cellular senescence is a biological “emergency brake” cells use to stop dividing. It’s an important anti-tumor mechanism, because it prevents cells from multiplying out of control. But after this “brake” has been pulled, senescent cells remain in the body, accumulating with age. And unlike normal cells, these cells secrete inflammatory molecules that harm neighboring cells and tissues.
UNITY has demonstrated in animal models that selectively eliminating senescent cells reverses or prevents a wide range of diseases, including osteoarthritis, atherosclerosis, eye diseases, and kidney diseases.
Our senolytic medicines target vulnerabilities unique to senescent cells, allowing us to eliminate them from the human body while leaving normal cells unaffected. We have pre-clinical programs in inflammatory joint diseases and ophthalmology.
| Research | Pre-clinical | Phase I |
|---|---|---|
| Inflammatory joint diseases | ||
| Ophthalmology | ||
| Atherosclerosis | ||
| Idiopathic pulmonary fibrosis | ||
| Chronic kidney disease |
Working at the frontier of biotechnology and medicine, UNITY improves the human condition by creating therapeutics that fundamentally improve how we age. With wonder and devotion, each of us advances company ideals and ambitions.
AT UNITY, WE EMBRACE
• Openness and individuality — daring to be different
• Integrity, compassion, and mutual respect
• Pragmatic realization of our dreams
• Balancing our commitment with fun
• Freedom to explore and courage to test
Members of UNITY’s management team have collectively moved 91 therapeutic candidates into human clinical trials and are responsible for the creation of 13 FDA-approved medicines.
We are located in the South San Francisco area and are looking to hire talented individuals to join our team. If you are interested in one of our open positions, please send your resume and cover letter to careers@unitybiotechnology.com.
Clinical Project Manager – BRIS.101
Research Associate, in vitro Pharmacology – BRIS.103
(Senior) Director, Pharmacometrics, Quantitative Pharmacology, and Modeling & Simulation – BRIS.105
Research Associate or Senior Research Associate, in vivo Pharmacology – BRIS.106
Senior Manager/Associate Director of Pharmaceutical Development – BRIS.107
Sr. Manager / Associate Director Manufacturing – BRIS.108
Senior Manager / Associate Director of Discovery and Development Program – BRIS.109
UNITY Biotechnology Appoints Additional Biotech Industry Veterans to Executive Team
September 21, 2017
SAN FRANCISCO, Sept. 21, 2017 /PRNewswire/ — UNITY Biotechnology, Inc. (“UNITY”), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced recent additions to its executive team.
UNITY Biotechnology Announces Extension of Series B Financing Bringing Total Round to $151 Million
August 17, 2017
SAN FRANCISCO, August 17, 2017 /PRNewswire/ — UNITY Biotechnology, Inc. (“UNITY”), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of an additional $35 million in Series B financing. This second close of the Series B, in addition to the initial close in fall of 2016, brings the total amount of this financing to $151 million.
Nature Medicine Study Describes a Novel Senolytic Molecule that Slows the Progression of Osteoarthritis
April 24, 2017
SAN FRANCISCO, April 24, 2017 /PRNewswire/ — UNITY Biotechnology, Inc. announced today the publication of new research in the journal Nature Medicine demonstrating that the selective elimination of senescent cells with a drug may delay, prevent, or even reverse the progression of osteoarthritis (OA)
UNITY Biotechnology Announces $116 Million Series B Financing
October 27, 2016
SAN FRANCISCO, Oct. 27, 2016 /PRNewswire/ — UNITY Biotechnology, Inc. (“UNITY”), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Ascentage Pharma and UNITY Biotechnology Announce Collaboration for the Development of Senolytic Healthspan Therapies
April 24, 2016
SAN FRANCISCO, April 24, 2016 /PRNewswire/ — Ascentage Pharma, a clinical-stage biopharmaceutical company focused on apoptosis-targeted oncology drug discovery and development, and UNITY Biotechnology, a San Francisco-based biopharmaceutical company focused on the development of medicines to improve healthspan, announced a worldwide collaboration to develop senolytic treatments for age-related disease.
Unity Biotechnology Launches with a Focus on Preventing and Reversing Diseases of Aging
February 03, 2016
SAN FRANCISCO–(BUSINESS WIRE)–Unity Biotechnology today announced that it is developing medicines to treat and eliminate age-related diseases and increase healthspan, or the amount of time an individual lives in good health. Unity‘s initial funding has been led by founding investor ARCH Venture Partners, with significant contributions from Venrock, WuXi, Mayo Clinic, Unity’s management team and others.
Office: 650-416-1192 | Fax: 415-656-4371
For media inquiries contact
media@unitybiotechnology.com
For career opportunities contact
careers@unitybiotechnology.com
© Copyright 2017 UNITY Biotechnology | Terms and Conditions
